Pneumococcal vaccine in elderly patients with COPD

Area of Science:

• Immunology
• Pulmonology
• Vaccinology

Background:

• Chronic obstructive pulmonary disease (COPD) is a significant health concern in the elderly population.
• Pneumococcal vaccination is recommended for individuals with COPD to prevent infections.
• Assessing post-vaccination antibody response in this vulnerable group is crucial for public health.

Purpose of the Study:

• To evaluate antibody levels in elderly patients with COPD one year after receiving the 14-valent pneumococcal vaccine.
• To compare antibody titers between vaccinated and unvaccinated COPD patients.
• To determine if antibody levels remain above protective thresholds in COPD patients post-vaccination.

Main Methods:

• Measurement of antibody concentrations against 12 serotypes of the pneumococcal vaccine in 12 vaccinated COPD patients (mean age 70) and 17 unvaccinated COPD patients (mean age 70).
• Geometric mean antibody concentration (GMAC) was calculated approximately 13 months post-vaccination.
• Comparison of GMAC with established minimally protective levels (250-300 ng/mL).

Main Results:

• Vaccinated COPD patients demonstrated GMAC above the minimally protective level for 10 out of 12 serotypes, one year post-vaccination.
• Antibody levels exceeded 700 ng/mL for nine serotypes in the vaccinated group, with an overall GMAC of 927 ng/mL.
• Unvaccinated COPD patients showed slightly higher GMAC (395 ng/mL) compared to healthy younger individuals (217 ng/mL).

Conclusions:

• Elderly individuals with COPD achieve and maintain adequate pneumococcal antibody titers for at least one year following vaccination.
• The 14-valent pneumococcal vaccine appears effective in eliciting a sustained protective immune response in COPD patients.
• Findings support the continued recommendation of pneumococcal vaccination for elderly patients with COPD.